Product Description
a matrix metalloproteinase inhibitor
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Procter and Gamble
Company Location: CINCINNATI OH 45202
Company CEO: Jon R. Moeller
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Failure|Myocardial Infarction|Cardiomegaly
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00067236 | P2 |
Completed |
Heart Failure|Myocardial Infarction|Cardiomegaly |
2004-12-01 |